Doctor suspended over Ozempic to partner

A UK medical tribunal suspended a doctor in October 2025 for nine months for secretly prescribing the GLP-1 medicines Ozempic and Wegovy, both brand names for semaglutide, to a man she was dating, without disclosing that she was the prescriber or that she was a doctor at all^[2]. On 17 August 2026, the BMJ reported that her suspension has since been extended, following a further hearing^[1]. This piece explains what the original tribunal found, what the BMJ update does and does not tell us, and why the case matters beyond one practitioner.

What the original tribunal found

The Medical Practitioners Tribunal Service (MPTS) heard the case in Manchester between 22 September and 1 October 2025^[3]. The doctor, who ran a private gynaecology and fertility practice in Hampstead, north London, was found to have written prescriptions for Ozempic and Wegovy for a man referred to in the proceedings as "Mr B" over a two-month period^[3], while falsely telling him the prescriptions had been signed off by a colleague at a clinic that did not exist^[2]. Press reporting of the tribunal's findings says she also used a false name on a dating app before Mr B discovered she was a doctor^[3]. Mr B told the tribunal he had assumed the prescriptions came from "some random doctor" before realising the truth^[3].

The tribunal found her dishonest and ruled her fitness to practise impaired. It said her dishonesty "would inevitably have an adverse impact upon public confidence in her and the medical profession as a whole" and that once she provided Mr B with a prescription, "this amounted to medical treatment and he became her patient"^[2].

The rule this case turns on

Press coverage of the tribunal's reasoning points to a long-standing GMC principle: doctors must avoid prescribing for themselves or for anyone with whom they have a close personal relationship^[4]. Where a prescription is written in those circumstances, the doctor is expected to be transparent about it, not to conceal it. Once a prescription is written, the recipient is treated as a patient, which is what turned the concealment into a fitness-to-practise matter rather than a purely private one.

The rule is not bureaucratic box-ticking. A treating clinician who is emotionally involved with the person in front of them is exactly the person least able to give an independent assessment of whether a GLP-1 receptor agonist is appropriate for that individual, what dose escalation looks like, and how to weigh the gastrointestinal and other adverse effects that the medicine's own label describes. A second, uninvolved clinician is the safeguard the system relies on, and it is the safeguard this case shows being removed.

What the August 2026 BMJ update adds, and what it does not

The BMJ's 17 August 2026 report, by journalist Clare Dyer, carries the headline "Doctor who prescribed Ozempic and Wegovy to her partner has suspension extended"^[1]. That headline, and the bibliographic record behind it, is the confirmed news hook for this piece. What it does not give, at least not without a subscription this piece could verify, is the length of the extension, the date of the further hearing, or the tribunal's stated reasoning for extending rather than lifting the suspension. Readers who want those specifics should go to the primary source once it is accessible, or to the MPTS's own published determination for this doctor's case.

This is a case involving an identifiable individual and a live disciplinary process. We are reporting only what has been independently confirmed through the tribunal's own findings as quoted in press coverage, plus the bibliographic fact that a further BMJ report exists and describes an extension. We are not speculating about what the later hearing considered or concluded.

Why this matters beyond one case

Ozempic and Wegovy are prescription-only medicines everywhere they are authorised, including the UK, precisely because a prescriber is meant to make an independent clinical assessment before recommending a GLP-1 receptor agonist. That assessment includes checking for contraindications, discussing gastrointestinal and other side effects, and deciding whether the medicine is appropriate for that person at all. A doctor prescribing for a partner, without disclosure and without an independent colleague reviewing the decision, removes exactly the safeguard the prescription-only system is built around.

The case also lands inside a broader story this site tracks closely: the surge in demand for GLP-1 medicines has pulled in telehealth prescribers, private clinics, and a genuine grey market of unregulated "research" semaglutide sold outside any pharmacy. In the UK, semaglutide is prescription-only under MHRA authorisation, and the country-specific rules on who can prescribe it, and what happens when that route is bypassed, are on our UK regulation pages. A single MPTS case does not tell you how common this kind of breach is. It does tell you that the regulator treats concealment around a GLP-1 prescription as seriously as it would treat concealment around any other prescription-only medicine.

For readers trying to place this case in context: it is not a story about whether Ozempic or Wegovy are safe medicines when properly prescribed. Both have large randomised-trial evidence bases behind their approved indications, summarised on our semaglutide overview. It is a story about what happens when the person writing the prescription and the person receiving it are not in an ordinary clinical relationship, and about how a regulator responds when that boundary is crossed and then concealed rather than disclosed.

If you are trying to work out whether a specific peptide or GLP-1 medicine is legal to prescribe, import, or possess where you live, our regulation hub covers each of the seven jurisdictions this site tracks, and the semaglutide peptide page has country-by-country detail alongside the primary trial data behind Ozempic, Rybelsus, and Wegovy's approved indications.